Novo Nordisk and Eli Lilly's weight-loss drugs offer substantial net health benefits and are also cost-effective at current prices – but will still pose an affordability challenge to US healthcare.

GLP-1s, fenofibrates reduce risk for diabetic macular edema AI in Medicine Artificial intelligence is a rapidly evolving field. Learn how and why it is being applied in clinical practice in multiple ...